Nihanthy Sreenath (@nihanthy) 's Twitter Profile
Nihanthy Sreenath

@nihanthy

๐ŸŽ—๏ธ Medical Oncologist | ๐ŸŽ“ Cancer Educator | ๐Ÿงฌ AYA, Breast, Gyn, GI Cancers | ๐Ÿ’‰ BMT & CAR-T | Passionate about evidence, equity & empathy in oncology

ID: 107409581

calendar_today22-01-2010 13:25:39

4 Tweet

20 Followers

61 Following

Sachin Sarcoma Society (@sachinsarcoma) 's Twitter Profile Photo

Organising 263 th #sarcoma #supportgroup meeting on this Sunday and have invited Dr Nihanthy Sreenath , #Medicaloncologist in Calcutta who will give #educational session on How to deal with #sideeffects faced due to #chemotherapy. Concerns of patients would be addressed.

Organising 263 th #sarcoma #supportgroup meeting on this Sunday and have invited Dr Nihanthy Sreenath , #Medicaloncologist in Calcutta who will give #educational session on How to deal with #sideeffects faced due to #chemotherapy. Concerns of patients would be addressed.
Dr Amol Akhade (@suyogcancer) 's Twitter Profile Photo

As an #ASCO25 Ambassador, Iโ€™ve started posting key abstract highlights on X โ€” and will continue over the coming days! ๐ŸŒ For colleagues in LMICs, I hope this thread-style coverage helps overcome barriers like paywalls, bandwidth, or time zones. ๐Ÿ’ผ For those in HICs, this is a

Sachin Sarcoma Society (@sachinsarcoma) 's Twitter Profile Photo

Organised 263 th #sarcoma #supportgroup meeting on last Sunday where Dr Nihanthy Sreenath gave talk on How to deal with sideeffects caused due to #chemotherapy. Concerns of patients were addressed. 82 patients joined. #awareness #education #companionship #cancer

Organised 263 th #sarcoma #supportgroup meeting on last Sunday where Dr <a href="/nihanthy/">Nihanthy Sreenath</a> gave talk on How to deal with sideeffects caused due to #chemotherapy. Concerns of patients were addressed. 82 patients joined. 
#awareness #education #companionship #cancer
Dr Sameer Rastogi (@samdoc_mamc) 's Twitter Profile Photo

We are pleased to share the preliminary results of SORASTOP, which investigates whether sorafenib can be discontinued in individuals with #desmoid tumors who are responding to treatment. Good early results. AIIMS, New Delhi ๐Ÿ‡ฎ๐Ÿ‡ณ Memorial Sloan Kettering Cancer Center ecancer.org/en/journal/artโ€ฆ OncoDaily

We are pleased to share the preliminary results of SORASTOP, which investigates whether sorafenib can be discontinued in individuals with #desmoid tumors who are responding to treatment. Good early results. <a href="/aiims_newdelhi/">AIIMS, New Delhi ๐Ÿ‡ฎ๐Ÿ‡ณ</a> <a href="/MSKCancerCenter/">Memorial Sloan Kettering Cancer Center</a>  ecancer.org/en/journal/artโ€ฆ <a href="/oncodaily/">OncoDaily</a>
Vivek Subbiah, MD (@viveksubbiah) 's Twitter Profile Photo

โญ๏ธ๐ŸšจDelighted to report ๐Ÿ‘‰๐ŸผEfficacy and safety of pralsetinib in RET fusion-positive solid tumors: Final data from the ARROW trial. | Journal of Clinical Oncology #RET #TissueAgnostic #PrecisionMedicine OncoAlert G Curigliano MD PhD ASCO #ASCO25 ascopubs.org/doi/10.1200/JCโ€ฆ

Dr Amol Akhade (@suyogcancer) 's Twitter Profile Photo

Excellent summary slides for current evidence for pancreatic cancer treatment . Useful for quick reference. @asco #asco25 taken from talk by Dr Brian Wolpin ๐Ÿ‘OncoAlert ONCO BRUNO

Excellent summary slides for current evidence for pancreatic cancer treatment . Useful for quick reference.  @asco #asco25 taken from talk by Dr Brian Wolpin ๐Ÿ‘<a href="/OncoAlert/">OncoAlert</a> <a href="/brunolarvol/">ONCO BRUNO</a>
Dr Sameer Rastogi (@samdoc_mamc) 's Twitter Profile Photo

Pleased to share Phase 2 trial results for low-dose regorafenib in relapsed synovial sarcoma. N=25, 76% previously exposed to pazopanib. 3-month progression-free rate: 56%. Median progression-free survival: 5 mths. ascopubs.org/doi/10.1200/GOโ€ฆ OncoDaily JCO Global Oncology

Pleased to share Phase 2 trial results for low-dose regorafenib in relapsed synovial sarcoma. 
N=25, 76% previously exposed to pazopanib. 3-month progression-free rate: 56%. Median progression-free survival: 5 mths. ascopubs.org/doi/10.1200/GOโ€ฆ
<a href="/oncodaily/">OncoDaily</a> <a href="/JCOGO_ASCO/">JCO Global Oncology</a>
Dr Amol Akhade (@suyogcancer) 's Twitter Profile Photo

When you treat metastatic CRPC in elderly person, polypharmacy and drug to drug interactions needs to noted . These are some common drug interactions with Abiraterone and Enzalutamide. Useful for clinical practice OncoAlert Kate Sears Oncology Brothers Yakup Ergรผn

When you treat metastatic CRPC in elderly person,  polypharmacy and drug to drug interactions needs to noted . These are some common drug interactions with Abiraterone and Enzalutamide.  Useful for clinical practice <a href="/OncoAlert/">OncoAlert</a> <a href="/medicalwatchBC/">Kate Sears</a> <a href="/OncBrothers/">Oncology Brothers</a> <a href="/dr_yakupergun/">Yakup Ergรผn</a>
Dr Amol Akhade (@suyogcancer) 's Twitter Profile Photo

Honored to be named among the Top 10 Digital Opinion Leaders at ASCO 2025 by LARVOL. In a time where borders blur in the digital world, X has become our global village โ€” a space where data, ideas, and experiences cross continents in seconds. For those of us from low- and

Praveen Kumar Marimuthu (@drmpk91) 's Twitter Profile Photo

Important work from ๐Ÿ‡ฎ๐Ÿ‡ณ presented at #MASCC25 by fellow YMOs Nihanthy Sreenath Psychosocial distress in AYA pts with cancer Dr Rahul Kumar, MD Scalp cooling to prevent chemo-induced alopecia in children with ALL ISMPO #SuppOnc

Important work from ๐Ÿ‡ฎ๐Ÿ‡ณ presented at #MASCC25 by fellow YMOs  
<a href="/nihanthy/">Nihanthy Sreenath</a> Psychosocial distress in AYA pts with cancer
<a href="/Dr_Rahul_AIIMS/">Dr Rahul Kumar, MD</a> Scalp cooling to prevent chemo-induced alopecia in children with ALL 
<a href="/ISMPOofficial/">ISMPO</a> 
#SuppOnc
Saad Nasir, MD (@saadnasir01) 's Twitter Profile Photo

Just wrapped up #MASCC2025 โœจ Presented x2 ๐ŸŽค๐Ÿ“Š, found an inspiring mentor Maryam Lustberg MD, MPH, FASCO ๐ŸŒŸ, made amazing friends (Dr Rahul Kumar, MD, Nihanthy Sreenath, Praveen Kumar Marimuthu) ๐Ÿค, and embraced Seattleโ€™s vibes. Grateful ๐Ÿ™ for the science, the stories, and a whole new lens on supportive care.

Just wrapped up #MASCC2025 โœจ Presented x2 ๐ŸŽค๐Ÿ“Š, found an inspiring mentor <a href="/maryam_lustberg/">Maryam Lustberg MD, MPH, FASCO</a> ๐ŸŒŸ, made amazing friends (<a href="/Dr_Rahul_AIIMS/">Dr Rahul Kumar, MD</a>, <a href="/nihanthy/">Nihanthy Sreenath</a>, <a href="/drmpk91/">Praveen Kumar Marimuthu</a>) ๐Ÿค, and embraced Seattleโ€™s vibes.

Grateful ๐Ÿ™ for the science, the stories, and a whole new lens on supportive care.
Nihanthy Sreenath (@nihanthy) 's Twitter Profile Photo

What a ride, Saad! ๐ŸŽค๐Ÿ”ฅ Your energy lit up #MASCC2025-proud to cheer you on through it all. Grateful for the science, the friendship, and the shared purpose in oncology & supportive care! ๐ŸŒŸ

Nihanthy Sreenath (@nihanthy) 's Twitter Profile Photo

Thank you to MASCC and OncoDaily. Grateful to be featured by @OncoDaily1 among global leaders in supportive oncology through the Multinational Association of Supportive Care in Cancer (MASCC). ๐ŸŒ๐Ÿ’™ #MASCC #Oncology #SupportiveCare

Nihanthy Sreenath (@nihanthy) 's Twitter Profile Photo

Thank you to MASCC and OncoDaily. Grateful to be featured by @OncoDaily1 among global leaders in supportive oncology through the Multinational Association of Supportive Care in Cancer (MASCC). ๐ŸŒ๐Ÿ’™ #MASCC #Oncology #SupportiveCare

Katherine Van Loon, MD, MPH (@kvanloonmd) 's Twitter Profile Photo

See this amazing example from NEJM by Dr. Nihanthy D. Sreenath Nihanthy Sreenath for inspiration: A Good Innings โ€” A Tale of Hope, Heartbreak, and Healing nej.md/4jMJteW #MedicalEthics #MedicalPractice